MPM BioImpact LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001687078

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallHealth TiltHigh Turnover how tags are computed

Q4 2024 · 47 positions · Total reported value $704.36M · Top-10 concentration 44.7% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 81.2% · 7 new · 21 cut · 11 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +31.4% · vs SPY +16.6% · Prev Value $1.29B — last quarter positions weighted by this quarter price moves · ranking

In its Q4 2024 13F filing, MPM BioImpact LLC disclosed 47 equity positions with a combined reported value of $704.36M. The filing implies a moderately concentrated portfolio: its ten largest positions account for 44.7% of reported value. HoldingsHub classifies the profile as Small / Health Tilt / High Turnover.

The largest disclosed positions as of Q4 2024 were CGEM ($93.16M), CRNX ($31.55M), EWTX ($28.82M). By sector, the heaviest allocations are Health Care 88.3%, Materials 0.4%. Versus the prior quarter, allocation shifted toward Health Care (+4.9pp) and away from Other (-4.6pp).

Versus the prior quarter, MPM BioImpact LLC opened 7 new positions, trimmed 21 and fully exited 11, a turnover rate of 81.2% of positions. The portfolio's overlap with the prior quarter was 67% of names.

The largest new positions opened in Q4 2024 were ZLAB ($20.95M), SRRK ($17.99M), CNTX ($15.44M).

Of the 11 positions fully exited versus the prior quarter, the largest were MDGL ($15.36M), KALV ($10.39M), VKTX ($7.66M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q4 2024)

  • ZLAB Zai Lab Ltd · $20.95M
  • SRRK SCHOLAR ROCK HLDG CORP · $17.99M
  • CNTX CONTEXT THERAPEUTICS INC · $15.44M
  • REPL REPLIMUNE GROUP INC · $11.50M
  • NUVB NUVATION BIO INC · $11.08M
  • VERA VERA THERAPEUTICS INC · $10.90M
  • IDYA IDEAYA BIOSCIENCES INC · $10.64M
  • UTHR UNITED THERAPEUTICS CORP DEL · $8.12M

Fully Exited (vs previous quarter)

  • MDGL MADRIGAL PHARMACEUTICALS INC · prev qtr: $15.36M
  • KALV KALVISTA PHARMACEUTICALS INC · prev qtr: $10.39M
  • VKTX VIKING THERAPEUTICS INC · prev qtr: $7.66M
  • NTLA INTELLIA THERAPEUTICS INC · prev qtr: $5.50M
  • ETNB 89BIO INC · prev qtr: $2.44M
  • RGNX REGENXBIO INC · prev qtr: $524.50K
  • SLDB SOLID BIOSCIENCES INC COM NEW · prev qtr: $80.28K

Insider Transactions (Form 4)

Latest MPM BioImpact LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

MPM BioImpact LLC, based in Boston, MA, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 37 positions worth $1.64B in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: BOSTON, MA, United States
  • SEC registration: 801-106989 (status: Approved), registered 2016-01-04
  • Regulatory AUM (Form ADV): $3.56B as of 2026-04-28
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 14 private funds, of which 3 hedge funds

Portfolio Structure

  • 37 positions · $1.64B reported value (Q2 2026)
  • Top 10 holdings = 55.3% of reported value
  • Largest position: CGEM (CULLINAN THERAPEUTICS INC) at 10.8%
  • Average position size: $44.32M

Sector Tilt

  • Health Care 98.7%
  • (classified holdings cover 99% of value)

Quarterly Activity

  • Q2 2026: 7 new, 7 added, 21 reduced, 11 exited
  • 2 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 88.3%
Materials 0.4%
Other 11.3%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 7.65M $93.16M 13.23%
13.23%
Hold
2 617.03K $31.55M 4.48%
4.48%
Add
3 1.08M $28.82M 4.09%
4.09%
Add
4 389.61K $26.90M 3.82%
3.82%
Reduce
5 160.63K $25.43M 3.61%
3.61%
Reduce
6 589.58K $24.38M 3.46%
3.46%
Add
7 346.40K $21.96M 3.12%
3.12%
Add
8 236.21K $21.13M 3.00%
3.00%
Add
9 800.00K $20.95M 2.98%
2.98%
New
10 702.98K $20.44M 2.90%
2.90%
Add
11 2.67M $19.79M 2.81%
2.81%
Add
12 434.77K $19.63M 2.79%
2.79%
Add
13 1.49M $18.42M 2.62%
2.62%
Add
14 416.14K $17.99M 2.55%
2.55%
New
15 315.23K $17.07M 2.42%
2.42%
Reduce
16 2.91M $16.98M 2.41%
2.41%
Add
17 391.02K $16.45M 2.33%
2.33%
Add
18 14.71M $15.44M 2.19%
2.19%
New
19 452.74K $13.83M 1.96%
1.96%
Reduce
20 313.82K $13.73M 1.95%
1.95%
Add
21 1.75M $13.41M 1.90%
1.90%
Hold
22 721.14K $12.92M 1.83%
1.83%
Add
23 1.02M $12.83M 1.82%
1.82%
Reduce
24 460.62K $12.81M 1.82%
1.82%
Add
25 3.09M $12.75M 1.81%
1.81%
Add
26 267.50K $12.43M 1.76%
1.76%
Reduce
27 8.57M $12.42M 1.76%
1.76%
Add
28 230.00K $12.31M 1.75%
1.75%
Add
29 950.00K $11.50M 1.63%
1.63%
New
30 4.16M $11.08M 1.57%
1.57%
New
31 257.79K $10.90M 1.55%
1.55%
New
32 414.04K $10.64M 1.51%
1.51%
New
33 2.27M $9.35M 1.33%
1.33%
Add
34 23.00K $8.12M 1.15%
1.15%
New
35 459.94K $7.81M 1.11%
1.11%
Add
36 197.21K $7.73M 1.10%
1.10%
Add
37 685.83K $7.56M 1.07%
1.07%
Add
38 1.61M $5.74M 0.81%
0.81%
Reduce
39 50.00K $4.23M 0.60%
0.60%
New
40 2.16M $3.97M 0.56%
0.56%
Reduce
41 2.39M $3.53M 0.50%
0.50%
Hold
42 559.55K $3.45M 0.49%
0.49%
New
43 1.11M $3.35M 0.48%
0.48%
Reduce
44 4.29M $2.79M 0.40%
0.40%
New
45 5.10M $2.75M 0.39%
0.39%
Hold
46 1.39M $2.32M 0.33%
0.33%
Reduce
47 1.23M $1.61M 0.23%
0.23%
Reduce

FAQ

What did MPM BioImpact LLC buy in 2024-Q4?

In its 2024-Q4 13F filing, MPM BioImpact LLC reported 47 equity positions worth $704.36M in aggregate; its largest disclosed positions were CGEM ($93.16M), CRNX ($31.55M), EWTX ($28.82M).

How large is MPM BioImpact LLC's portfolio?

MPM BioImpact LLC reported $704.36M of long equity holdings across 47 positions as of 2024-Q4. Top-10 holdings account for 44.7% of reported value.

What is MPM BioImpact LLC's investment style?

HoldingsHub classifies the portfolio as Small / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/mpm-bioimpact/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →